Treatments for Latrodectism-A Systematic Review on Their Clinical Effectiveness

Nicole M Ryan, Nicholas A Buckley, Andis Graudins, Nicole M Ryan, Nicholas A Buckley, Andis Graudins

Abstract

Latrodectism or envenomation by widow-spiders is common and clinically significant worldwide. Alpha-latrotoxin is the mammalian-specific toxin in the venom that results in toxic effects observed in humans. Symptoms may be incapacitating and include severe pain that can persist for days. The management of mild to moderate latrodectism is primarily supportive while severe cases have variously been treated with intravenous calcium, muscle relaxants, widow-spider antivenom and analgesic opioids. The object of this systematic review is to examine the literature on the clinical effectiveness of past and current treatments for latrodectism. MEDLINE, EMBASE and Google Scholar were searched from 1946 to December 2016 to identify clinical studies on the treatment of latrodectism. Studies older than 40 years and not in English were not reviewed. There were only two full-publications and one abstract of placebo-controlled randomised trials on antivenom use for latrodectism. Another two randomised comparative trials compared the route of administration of antivenom for latrodectism. There were fourteen case series (including two abstracts), fourteen case reports and one letter investigating drug treatments for latrodectism with the majority of these also including antivenom for severe latrodectism. Antivenom with opioid analgesia is often the major treatment reported for latrodectism however; recent high quality evidence has cast doubt on the clinical effectiveness of this combination and suggests that other treatments need to be investigated.

Keywords: antivenom; envenomation; red-back spider; treatment; widow spider.

Conflict of interest statement

The authors declare no conflict of interest. The funding sponsors had no role in the writing of this manuscript.

Figures

Figure 1
Figure 1
Graph of Pain Responders (Treatment Success) to IV Antivenom compared to Pain Responders (Treatment Success) to IM Antivenom or Placebo. # response at 24 h not at specified primary outcome.
Figure 2
Figure 2
RevMan meta-analysis and Forest Plot of the five randomised controlled trials on antivenom for pain from latrodectism.

References

    1. Clark R.F., Wethern-Kestner S., Vance M.V., Gerkin R. Clinical presentation and treatment of black widow spider envenomation: A review of 163 cases. Ann. Emerg. Med. 1992;21:782–787. doi: 10.1016/S0196-0644(05)81021-2.
    1. Saucier J.R. Arachnid envenomation. Emerg. Med. Clin. N. Am. 2004;22:405–422. doi: 10.1016/j.emc.2004.01.006.
    1. Thorp R.W., Woodson W.D. The Black Widow Spider: (Formerly: Black Widow; America’s Most Poisonous Spider) University of North Carolina Press; Raleigh, NC, USA: 1945.
    1. Isbister G.K., Brown S.G., Miller M., Tankel A., Macdonald E., Stokes B., Ellis R., Nagree Y., Wilkes G.J., James R., et al. A randomised controlled trial of intramuscular vs. intravenous antivenom for latrodectism—The RAVE study. QJM. 2008;101:557–565.
    1. Isbister G.K., Fan H.W. Spider bite. Lancet. 2011;378:2039–2047. doi: 10.1016/S0140-6736(10)62230-1.
    1. Nicholson G.M., Graudins A. Spiders of medical importance in the Asia-Pacific: Atracotoxin, latrotoxin and related spider neurotoxins. Clin. Exp. Pharmacol. Physiol. 2002;29:785–794. doi: 10.1046/j.1440-1681.2002.03741.x.
    1. Monte A.A., Bucher-Bartelson B., Heard K.J. A US Perspective of Symptomatic Latrodectus spp. Envenomation and Treatment: A national poison data system review. Ann. Pharmacother. 2011;45:1491–1498.
    1. Hlubek M.D., Stuenkel E.L., Krasnoperov V.G., Petrenko A.G., Holz R.W. Calcium-Independent Receptor for a-Latrotoxin and Neurexin 1a Facilitate Toxin-Induced Channel Formation: Evidence That Channel Formation Results from Tethering of Toxin to Membrane. Mol. Pharmacol. 2000;57:519–528.
    1. Lelianova V.G., Davletov B.A., Sterling A., Rahman M.A., Grishin E.V., Totty N.F., Ushkaryov Y.A. α-Latrotoxin Receptor, Latrophilin, Is a Novel Member of the Secretin Family of G Protein-coupled Receptors. J. Biol. Chem. 1997;272:21504–21508. doi: 10.1074/jbc.272.34.21504.
    1. Khvotchev M., Südhof T.C. α-latrotoxin triggers transmitter release via direct insertion into the presynaptic plasma membrane. EMBO J. 2000;19:3250–3262. doi: 10.1093/emboj/19.13.3250.
    1. Isbister G.K., Gray M.R. Latrodectism: A prospective cohort study of bites by formally identified redback spiders. Med. J. Aust. 2003;179:88–91.
    1. Maretić Z. Latrodectism: Variations in clinical manifestations provoked by Latrodectus species of spiders. Toxicon. 1983;21:457–466. doi: 10.1016/0041-0101(83)90123-X.
    1. Ballantyne J.C., Carr D.B., deFerranti S., Suarez T., Lau J., Chalmers T.C., Angelillo I.F., Mosteller F. The Comparative Effects of Postoperative Analgesic Therapies on Pulmonary Outcome: Cumulative Meta-Analyses of Randomized, Controlled Trials. Anesth. Analg. 1998;86:598–612. doi: 10.1213/00000539-199803000-00032.
    1. Monte A.A. Black widow spider (Latrodectus mactans) antivenom in clinical practice. Cur. Pharm. Biotechnol. 2012;13:1935–1939. doi: 10.2174/138920112802273335.
    1. Clark R.F. The Safety and Efficacy of Antivenin Latrodectus mactans. J. Toxicol. Clin. Toxicol. 2001;39:125–127. doi: 10.1081/CLT-100103827.
    1. Key G.F. A comparison of calcium gluconate and methocarbamol (Robaxin) in the treatment of latrodectism (black widow spider envenomation) Am. J. Trop. Med. Hyg. 1981;30:273–277.
    1. Ryan P.J. Preliminary report: Experience with the use of dantrolene sodium in the treatment of bites by the black widow spider Latrodectus hesperus. J. Toxicol. Clin. Toxicol. 1984;21:487–489. doi: 10.3109/15563658308990436.
    1. Timms P.K., Gibbons R.B. Latrodectism—Effects of the black widow spider bite. West. J. Med. 1986;144:315–317.
    1. Binder L.S. Acute arthropod envenomation. Incidence, clinical features and management. Med. Toxicol. Adv. Drug Exp. 1989;4:163–173. doi: 10.1007/BF03259994.
    1. O’Malley G.F., Dart R.C., Kuffner E.F. Successful treatment of latrodectism with antivenin after 90 h. N. Engl. J. Med. 1999;340:657. doi: 10.1056/NEJM199902253400816.
    1. Graudins A. Medical Toxicology. Lippincott Williams & Wilkins; Philadelphia, PA, USA: 2004.
    1. Hahn L., Lewin N. In: Goldfrank’s Toxicologic Emergencies. Flomenbaum N.E., Goldfrank L.R., Hoffmanm R.S., Howland M.A., Lewin N.A., LS N., editors. McGraw-Hill; New York, NY, USA: 2006.
    1. Gutierrez J.M., Leon G., Lomonte B. Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation. Clin. Pharmacokinet. 2003;42:721–741. doi: 10.2165/00003088-200342080-00002.
    1. Rivière G., Choumet V., Audebert F., Sabouraud A., Debray M., Scherrmann J.-M., Bon C. Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: Toward an optimization of antivenom therapy. J. Pharmacol. Exp. Ther. 1997;281:1–8.
    1. Isbister G.K., Graudins A., White J., Warrell D. Antivenom Treatment in Arachnidism. J. Toxicol. Clin. Toxicol. 2003;41:291–300. doi: 10.1081/CLT-120021114.
    1. Isbister G.K. Antivenom efficacy or effectiveness: the Australian experience. Toxicology. 2010;268:148–154. doi: 10.1016/j.tox.2009.09.013.
    1. Ellis R.M., Sprivulis P.C., Jelinek G.A., Banham N.D., Wood S.V., Wilkes G.J., Siegmund A., Roberts B.L. A double-blind, randomized trial of intravenous versus intramuscular antivenom for red-back spider envenoming. Emerg. Med. Australas. 2005;17:152–156. doi: 10.1111/j.1742-6723.2005.00720.x.
    1. Stanford C., Bush S., Clark R., Arnold T., Haynes J., Holstege C., Bogdan G., Garcia W., Smith J., Dart R. Clinical Toxicology. Informa Healthcare; New York, NY, USA: 2007. A new F(ab)2 antivenom for widow spider envenomation (Latrodectism)
    1. Isbister G.K. Safety of i.v. administration of redback spider antivenom. Intern. Med. J. 2007;37:820–822.
    1. Graudins A., Padula M., Broady K., Nicholson G.M. Red-back spider (Latrodectus hasselti) antivenom prevents the toxicity of widow spider venoms. Ann. Emerg. Med. 2001;37:154–160. doi: 10.1067/mem.2001.113033.
    1. Daly F.F.S., Daly F., Hill R.E., Bogdan G.M., Dart R.C. Neutralization of Latrodectus mactans and L. hesperus Venom by Redback Spider (L. hasseltii) Antivenom. J. Toxicol. Clin. Toxicol. 2001;39:119–123. doi: 10.1081/CLT-100103826.
    1. Jelinek G.A. Widow spider envenomation (latrodectism): A worldwide problem. Wilderness Environ. Med. 1997;8:226–231. doi: 10.1580/1080-6032(1997)008[0226:WSELAW];2.
    1. Hoyte C.O., Cushing T.A., Heard K.J. Anaphylaxis to black widow spider antivenom. Am. J. Emerg. Med. 2012;30:836.e1-2. doi: 10.1016/j.ajem.2011.03.017.
    1. Murphy C.M., Hong J.J., Beuhler M.C. Anaphylaxis with Latrodectus Antivenin Resulting in Cardiac Arrest. J. Med. Toxicol. 2011;7:317–321. doi: 10.1007/s13181-011-0183-1.
    1. Wiener S. Red back spider bite in Australia: An analysis of 167 cases. Med. J. Aust. 1961;48:44–49.
    1. Keegan H.L. Effectiveness of Latrodectus tredecimguttatus antivenin in protecting laboratory mice against effects of intraperitoneal injections of Latrodectus mactans venom. Am. J. Trop. Med. Hyg. 1955;4:762–764.
    1. Sutherland S.K., Trinca J.C. Survey of 2144 cases of red-back spider bites: Australia and New Zealand, 1963–1976. Med. J. Aust. 1978;2:620–623.
    1. Jelinek G.A., Banham N.D., Dunjey S.J. Red-back spider-bites at Fremantle Hospital, 1982–1987. Med. J. Aust. 1989;150:693–695.
    1. Mead H.J., Jelinek G.A. Red-back spider bites to Perth children, 1979-1988. J. Paediatr. Child Health. 1993;29:305–308. doi: 10.1111/j.1440-1754.1993.tb00518.x.
    1. Anderson P. Spider bites and scorpion stings. In: Rakel R., editor. Conn’s Current Therapy. W.B. Saunders; Philadelphia, PA, USA: 1988. pp. 1000–1002.
    1. Kunkel D. Arthropod envenomations. Emerg. Med. Clin. N. Am. 1984;2:579–586.
    1. Rees R.S., Campbell D. Spider bites. In: Auerbach P., Geehr E., editors. Management of Wilderness and Environmental Emergencies. CV Mosby Company; St. Louis, MO, USA: 1989. pp. 548–549.
    1. Sutherland S. Treatment of arachnid poisoning in Australia. Aust. Fam. Physician. 1996;5:305–312.
    1. Mollison L., Liew D., McDermott R., Hatch F. Red-back spider envenomation in the red centre of Australia. Med. J. Aust. 1994;161:704–705.
    1. Dzelalija B., Medic A. Latrodectus bites in Northern Dalmatia, Croatia: Clinical, laboratory, epidemiological, and therapeutical aspects. Croatian Med. J. 2003;44:135–138.
    1. Trethewy C.E., Bolisetty S., Wheaton G. Red-back spider envenomation in children in Central Australia. Emerg. Med. (Fremantle, W.A.) 2003;15:170–175. doi: 10.1046/j.1442-2026.2003.00435.x.
    1. Byrne G.C., Pemberton P.J. Red-back spider (Latrodectus mactans hasselti) envenomation in a neonate. Med. J. Aust. 1983;2:665–666.
    1. Nordt S.P., Lee A., Sasaki K., Clark R., Cantrell F.L. Retrospective review of black widow antivenom use. Clin. Toxicol. 2010;48:627.
    1. Basanou E., Kalostou A., Sofidiotou V., Fountas K., Kalantzopoulos D., Papathanassiou V., Neou P. Treatment of black widow spider (Latrodectus mactans) envenomation: A review of 53 cases. Clin. Toxicol. 2015;53:281.
    1. Fatovich D.M., Dunjey S.J., Constantine C.J., Hirsch R.L. Successful treatment of red-back spider bite using a Bier’s block technique. Med. J. Aust. 1999;170:342–343.
    1. Isbister G.K., O’Leary M., Miller M., Brown S.G.A., Ramasamy S., James R., Schneider J.S. A comparison of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow) spider antivenom. Br. J. Clin. Pharmacol. 2008;65:139–143. doi: 10.1111/j.1365-2125.2007.03004.x.
    1. Dart R., Heard K., Bush S., Arnold T., Sutter M., Campagne D., Holstege C., Seifert S., Quan D., Borron S.W. Clinical Toxicology. Taylor & Francis Ltd.; Abingdon, UK: 2016. A Phase III Clinical Trial of Analatro (R)[Antivenin Latrodectus (Black Widow) Equine Immune F(ab’)2] in Patients with Systemic Latrodectism.
    1. Dart R.C., Bogdan G., Heard K., Bucher B.B., Garcia-Ubbelohde W., Bush S., Arnold T., Clark R.C., Hendey G.W., Holstege C., et al. A randomized, double-blind, placebo-controlled trial of a highly purified equine F(ab)2 antibody black widow spider antivenom. Ann. Emerg. Med. 2013;61:458–467. doi: 10.1016/j.annemergmed.2012.10.008.
    1. Isbister G.K., Page C.B., Buckley N.A., Fatovich D.M., Pascu O., MacDonald S.P., Calver L.A., Brown S.G. Randomized controlled trial of intravenous antivenom versus placebo for latrodectism: The second Redback Antivenom Evaluation (RAVE-II) study. Ann. Emerg. Med. 2014;64:620–628. doi: 10.1016/j.annemergmed.2014.06.006.
    1. Loten C., Stokes B., Worsley D., Seymour J.E., Jiang S., Isbister G.K. A randomised controlled trial of hot water (45 °C) immersion versus ice packs for pain relief in bluebottle stings. Med. J. Aust. 2006;184:329–333.
    1. Berthier F., Potel G., Leconte P., Touze M.-D., Baron D. Comparative study of methods of measuring acute pain intensity in an ED. Am. J. Emerg. Med. 1998;16:132–136. doi: 10.1016/S0735-6757(98)90029-8.
    1. Bijur P.E., Latimer C.T., Gallagher E.J. Validation of a verbally administered numerical rating scale of acute pain for use in the emergency department. Acad. Emerg. Med. 2003;10:390–392. doi: 10.1111/j.1553-2712.2003.tb01355.x.
    1. Ferreira-Valente M.A., Pais-Ribeiro J.L., Jensen M.P. Validity of four pain intensity rating scales. Pain. 2011;152:2399–2404. doi: 10.1016/j.pain.2011.07.005.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit